Data gathered: January 14
Alternative Data for Sangamo Therapeutics
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Job Posts | 3 | Sign up | Sign up | Sign up | |
Sentiment | 100 | Sign up | Sign up | Sign up | |
Webpage traffic | 24,000 | Sign up | Sign up | Sign up | |
Employee Rating | 78 | Sign up | Sign up | Sign up | |
Google Trends | 19 | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Facebook Engagement | N/A | Sign up | Sign up | Sign up | |
Facebook Followers | 887 | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 60 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 13,046 | Sign up | Sign up | Sign up | |
Twitter Followers | 3,975 | Sign up | Sign up | Sign up | |
News Mentions | 1 | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up | |
Business Outlook | 35 | Sign up | Sign up | Sign up | |
Linkedin Employees | 291 | Sign up | Sign up | Sign up |
About Sangamo Therapeutics
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
Price | $1.03 |
Target Price | Sign up |
Volume | 4,670,000 |
Market Cap | $563M |
Year Range | $0.32 - $2.87 |
Dividend Yield | 0% |
Analyst Rating | 71% buy |
Industry | Biotechnology |
In the news
Reviewing Sangamo Therapeutics (NASDAQ:SGMO) and Avalon GloboCare (NASDAQ:ALBT)January 12 - ETF Daily News |
|
Geode Capital Management LLC Purchases 272,123 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)January 9 - ETF Daily News |
|
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOJanuary 7 - Finnhub |
|
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025January 7 - Yahoo |
|
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $7.00January 2 - ETF Daily News |
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & MoreJanuary 2 - Yahoo |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q3 '24 | 49M | 11M | 38M | 11M | 11M | 0.044 |
Q2 '24 | 360,000 | 13M | -13M | -36M | -33M | -0.180 |
Q1 '24 | 480,000 | 17M | -17M | -49M | -45M | -0.270 |
Q4 '23 | 2M | 100,000 | -100,000 | -60M | -58M | -0.340 |
Q3 '23 | 9.4M | 59M | -49M | -104M | -17M | -0.590 |
Insider Transactions View All
BIOGEN INC. filed to sell 17,652,466 shares at $0.5. September 28 '23 |
Similar companies
Read more about Sangamo Therapeutics (SGMO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Sangamo Therapeutics?
The Market Cap of Sangamo Therapeutics is $563M.
What is the current stock price of Sangamo Therapeutics?
Currently, the price of one share of Sangamo Therapeutics stock is $1.03.
How can I analyze the SGMO stock price chart for investment decisions?
The SGMO stock price chart above provides a comprehensive visual representation of Sangamo Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sangamo Therapeutics shares. Our platform offers an up-to-date SGMO stock price chart, along with technical data analysis and alternative data insights.
Does SGMO offer dividends to its shareholders?
As of our latest update, Sangamo Therapeutics (SGMO) does not offer dividends to its shareholders. Investors interested in Sangamo Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sangamo Therapeutics?
Some of the similar stocks of Sangamo Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.